Skip to main content
SpringerLink
Log in

Selektive Östrogenrezeptormodulatoren (SERMs) bei Osteoporose

  • Chapter
Osteoporose

Part of the book series: Praktische Orthopädie ((PRAKORTHO,volume 41))

  • 109 Accesses

Zusammenfassung

Etwa ein Viertel aller postmenopausalen Frauen in Europa haben nach jüngsten Berechnungen eine Osteoporose [2], legt man die WHO-Definition zugrunde, die von einer Knochendichte von mindestens 2,5 Standardabweichungen unterhalb des Mittelwertes junger knochengesunder Frauen ausgeht (sogenannter T-Score; WHO 1994). Zwischen Knochenmasse und Frakturrisiko besteht eine inverse Beziehung, daher kann eine Messung der Knochendichte die Abschätzung des Frakturrisikos ermöglichen, ohne jedoch eine sichere Identifizierung des Individuums, das in der Zukunft eine Fraktur erfahren wird, zu leisten. Obwohl Frauen und Männer offenbar den gleichen Gehalt an Knochenmineralsubstanz innerhalb der Wirbelkörper aufweisen [29], ist die Inzidenz der Osteoporose bei Frauen größer und wird in der Zukunft wahrscheinlich weiter ansteigen, nicht zuletzt wegen der größeren und steigenden Lebenserwartung der Frauen (Abb. 1 [12]).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

Literatur

  1. Consensus Development Statement (1997) Who are candidates for prevention and treatment for osteoporosis? Osteoporos Int 7:1–6

    Google Scholar 

  2. Cooper C, Barrett-Connor E (1996) Epidemiology of osteoporosis. In: Papapoulos SE, Lips P, Pols HAP, Johnston CC, Delmas PD (Hrsg) (1996) Osteoporosis. Proceedings of the 1996 world congress on osteoporosis. Amsterdam, The Netherlands, 18-23 May, 1996. Elsevier Science BV, Amsterdam, S 75-77

    Google Scholar 

  3. Cummings SR, Browner WS, Bauer D et al (1998) Endogenous hormones and the risk of hip and vertebral fractures among older women. N Engl J Med 339:733–738

    Article  PubMed  CAS  Google Scholar 

  4. Cummings SR, Eckert S, Krueger KA et al (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 281:2189–2197

    Article  PubMed  CAS  Google Scholar 

  5. Davies GC, Huster WJ, Shen W et al (1999) Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women. Menopause 6:188–195

    Article  PubMed  CAS  Google Scholar 

  6. Delmas PD, Bjarnason NH, Mitlak BH et al (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641–1647

    Article  PubMed  CAS  Google Scholar 

  7. De Souza MJ, Miller BE, Sequenzia LC et al (1997) Bone health is not affected by luteal phase abnormalities and decreased ovarian progesterone production in female runners. J Clin Endocrinol Metab 82:2867–2876

    Article  PubMed  Google Scholar 

  8. Dören M (1999) An assessment of hormone replacement therapy to prevent postmenopausal osteoporosis. Osteoporos Int (Suppl 2):53–61

    Google Scholar 

  9. Eastell R (1998) Treatment of postmenopausal osteoporosis. N Engl J Med 338: 736–746

    Article  PubMed  CAS  Google Scholar 

  10. Ettinger B, Pressman A, Sklarin P et al (1998) Associations between low levels of serum estradiol, bone density, and fractures among elderly women: the study for osteoporotic fractures. J Clin Endocrinol Metab 83:2239–2243

    Article  PubMed  CAS  Google Scholar 

  11. Ettinger B, Black D, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 282:637–645

    Article  PubMed  CAS  Google Scholar 

  12. European Commission and European Foundation for Osteoporosis (1998) Summary Report on Osteoporosis in the European Community — Action for Prevention

    Google Scholar 

  13. European Consensus Development Conference on Menopause (1996) Hum Reprod 83:693–700

    Google Scholar 

  14. Fisher B, Costantino JO, Wickerham DL et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-l Study. J Natl Cancer Inst 90:1371–1388

    Article  PubMed  CAS  Google Scholar 

  15. Gambacciani M, Spinetti A, de Simone L et al (1995) Postmenopausal bone loss of the proximal femur: estimated contributions of menopause and aging. Menopause 2:169–174

    Google Scholar 

  16. Heaney RP, Draper MW (1997) Raloxifene and estrogen: comparative bone-remodeling kinetics. J Clin Endocrinol Metab 82:3425–3429

    Article  PubMed  CAS  Google Scholar 

  17. Jilka RL (1998) Cytokines, bone remodeling, and estrogen deficiency: a 1998 update. Bone 23:75–81

    Article  PubMed  CAS  Google Scholar 

  18. Jordan VC, Morrow M (1999) Tamoxifen, raloxifene, and the prevention of breast cancer. Endocr Rev 20:253–278

    Article  PubMed  CAS  Google Scholar 

  19. Kristensen B, Ejlertsen B, Dalgaard P et al (1994) Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J Clin Oncol 12:992–997

    PubMed  CAS  Google Scholar 

  20. Lindsay R, Tohme JF (1990) Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet Gynecol 76:290–295

    PubMed  CAS  Google Scholar 

  21. Love RR, Barden HS, Mazess RB et al (1994) Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Int Med 154:2585–2588

    Article  CAS  Google Scholar 

  22. Meunier PJ, Vognot E, Garnero P et al (1999) Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Osteoporos Int 10:330–336

    Article  PubMed  CAS  Google Scholar 

  23. National Osteoporosis Foundation (1998) Status Report. Osteoporosis: Review of the evidence for prevention, diagnosis, and treatment and cost-effectiveness analysis. Osteoporos Int 8 (Suppl 4):3–88

    Article  Google Scholar 

  24. Nilas L, Christiansen C (1987) Bone mass and ist relationship to age and the menopause. J Clin Endocrinol Metab 65:697–702

    Article  PubMed  CAS  Google Scholar 

  25. Nordin BEC, Need AG, Bridges A et al (1992) Relative contributions of years since menopause, age, and weight to vertebral density in postmenopausal women. J Clin Endocrinol Metab 74:20–23

    Article  PubMed  CAS  Google Scholar 

  26. Powles TJ, Hickish T, Kanis JA et al (1996) Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14:78–84

    PubMed  CAS  Google Scholar 

  27. Prior JC, Vigna YM, Schechter MT et al (1990) Spinal bone loss and ovulatory disturbances. N Engl J Med 323:1221–1227

    Article  PubMed  CAS  Google Scholar 

  28. Quigley MET, Martin PL, Burnier AM et al (1987) Estrogen therapy arrests bone loss in elderly women. Am J Obstet Gynecol 156:1516–1523

    PubMed  CAS  Google Scholar 

  29. Seeman E (1998) Editorial: Growth in bone mass and size — are racial and gender differences in bone mineral density more apparent than real? J Clin Endocrinol Metab 83:1414–1419

    Article  PubMed  CAS  Google Scholar 

  30. Stone K, Bauer DC, Black DM et al (1998) Hormonal predictors of bone loss in elderly women: a prospective study. J Bone Min Res 13:1167–1174

    Article  CAS  Google Scholar 

  31. Ward RL, Morgen G, Dalley D et al (1993) Tamoxifen reduces bone turnover and prevents lumbar spine and femoral bone loss in early postmenopausal women. Bone Min 22:187–194

    Article  Google Scholar 

  32. WHO (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series, 843, Geneva

    Google Scholar 

Download references

Authors
  1. M. Dören
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik Fleetinsel, Admiralitätstr. 3, 20459, Hamburg, Deutschland

    Achim Hedtmann

  2. Albert-Schweitzer-Str. 9a, München-Unterhaching, Deutschland

    Siegfried Götte

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Dören, M. (2002). Selektive Östrogenrezeptormodulatoren (SERMs) bei Osteoporose. In: Hedtmann, A., Götte, S. (eds) Osteoporose. Praktische Orthopädie, vol 41. Steinkopff, Heidelberg. https://doi.org/10.1007/978-3-642-57442-9_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-57442-9_9

  • Publisher Name: Steinkopff, Heidelberg

  • Print ISBN: 978-3-7985-1300-6

  • Online ISBN: 978-3-642-57442-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation